FOLH1 and digestive system neuroendocrine tumor, grade 1/2: Targeted radionuclide therapy (TRT), in particular, has generated a lot of interest within the oncology and nuclear medicine communities due to the recent clinical success of Luthathera® ([177Lu]Lu-DOTATATE) for the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and Pluvicto® ([177Lu]Lu-PSMA-617) for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) (Hennrich and Eder 2022; Hennrich et al. 2019).